Ernexa Therapeutics (ERNA) vs Propanc Biopharma (PPCB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Propanc Biopharma is the larger company by market cap ($4.6 million vs $4.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ERNA | PPCB |
|---|---|---|
| Share price | $2.49 | $0.471 |
| Market cap | $4.06M | $4.63M |
| 1-day change | +4.18% | -5.55% |
| EPS (TTM) | $-13.63 | $-17.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $71.50 | $48.75 |
| 52-week low | $2.14 | $0.46 |
| Distance from 52-week high | -96.52% | -99.03% |
| Analyst consensus | none | — |
| Avg. price target upside | +1104.82% | — |
| Average volume | 472.81K | 1.79M |
| Shares outstanding | 1.63M | 9.83M |
| Employees | 5 | 2 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Ernexa Therapeutics
ERNA stock →Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis.
Healthcare · Biotechnology · 5 employees
About Propanc Biopharma
PPCB stock →Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies.
Healthcare · Biotechnology · 2 employees
ERNA vs PPCB FAQ
Which is bigger, Ernexa Therapeutics or Propanc Biopharma?
Propanc Biopharma (PPCB) is larger, with a market capitalization of $4.63M compared with $4.06M for Ernexa Therapeutics (ERNA).
Are Ernexa Therapeutics and Propanc Biopharma in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.